Xilio Therapeutics
About: Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).
Employees: 73
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
2.39% more ownership
Funds ownership: 43.52% [Q1] → 45.9% (+2.39%) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 5 [Q1] → 5 (+0) [Q2]
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
1% less capital invested
Capital invested by funds: $16.3M [Q1] → $16.2M (-$157K) [Q2]
3% less funds holding
Funds holding: 35 [Q1] → 34 (-1) [Q2]
60% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 10
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Leerink Partners Daina Graybosch | 186%upside $2 | Outperform Initiated | 6 Aug 2025 |
Financial journalist opinion
Based on 3 articles about XLO published over the past 30 days









